Molecular Glues Market Size Projected to Reach USD 11.59 Billion by 2035

According to Precedence Research, the global molecular glues market size is projected to expand from USD 2.65 billion in 2025 to approximately USD 11.59 billion by 2035, with a robust CAGR of 15.90% between 2026 and 2035. This surge is fueled by advancements in targeted protein degradation, technological breakthroughs in structural biology, and the accelerating integration of AI in molecular glue discovery. As the market gains momentum, it promises to revolutionize treatment strategies for chronic diseases such as cancer, neurodegeneration, and autoimmune disorders.

Where Data Meets Strategic Clarity 📥 View Sample Pages of the Complete Report 👉 https://www.precedenceresearch.com/sample/8260

The Role of AI in Advancing Molecular Glues

Artificial intelligence (AI) is revolutionizing the molecular glues market by expediting the discovery and optimization of molecular glue degraders (MGDs). AI enables the rational design of these glues, allowing researchers to target previously "undruggable" proteins. This reduces research timelines and enhances drug development efficiency, particularly for conditions like cancer and neurodegenerative diseases.

Moreover, AI's integration into structural biology further accelerates the creation of glues that can engage E3 ligases to degrade harmful proteins, such as those associated with chronic diseases.

🔗 What's Fueling the Next Wave of Growth? 👉 https://www.precedenceresearch.com/molecular-glues-market

What's Driving the Growth of Molecular Glues?

• Innovation in Oncology: Molecular glues are proving transformative in cancer treatment, particularly in targeted therapies for solid tumors and hematologic malignancies.

• Advancements in Neurology: The potential applications in Alzheimer's, Parkinson's, and neurodegenerative diseases are also driving market expansion.

• High-Efficiency Targeting: Molecular glues are capable of inducing protein interactions that were previously considered unachievable with traditional drug mechanisms.

➡️ Become a valued research partner with us https://www.precedenceresearch.com/schedule-meeting

Opportunities and Trends in the Molecular Glues Market

Molecular glues are revolutionizing how we approach drug development by providing a more targeted, effective way to degrade disease-causing proteins. As research and development continue to expand, there is growing potential to create treatments for diseases that were once deemed untreatable.

The increasing focus on AI and machine learning is one of the major trends driving this market. Additionally, there is a noticeable rise in the adoption of phenotypic screening and structure-based drug design, significantly reducing R&D timelines.

🔓 Instant Access. Zero Waiting. 📥 Buy the Premium Market Research Report Now 👉 https://www.precedenceresearch.com/checkout/8260

Molecular Glues Market Regional Outlook

North America led the molecular glues market with a 42% market share in 2025. The region's dominance is attributed to its well-established healthcare infrastructure, cutting-edge research institutions, and strong venture capital support for biotech startups. Strategic partnerships between big pharma and biotech companies are accelerating the clinical development of molecular glue candidates.

Asia-Pacific is expected to grow at the fastest CAGR of approximately 16.2% from 2026 to 2035. Key drivers include increasing investments in biotechnology and pharmaceutical research, particularly in China, Japan, and India. The rising prevalence of chronic diseases, combined with expanding healthcare infrastructure and government support, is expected to propel the region's growth.

Note: This report is readily available for immediate delivery. We can review it with you in a meeting to ensure data reliability and quality for decision-making.

Try Before You Buy - Get the Sample Report@ https://www.precedenceresearch.com/sample/8260

Molecular Glues Market Segment Insights

🔸 Type Insights

Monovalent Molecular Glues Dominated in 2025
The monovalent molecular glues segment held the largest market share of 62.0% in 2025. This dominance is driven by their strong drug-like properties, closely aligned with traditional small-molecule drug development. Their small size enables better cell permeability, improved tissue distribution, and higher oral bioavailability, making them highly effective and widely adopted.

Bivalent/Next-Generation Glues Gaining Momentum
The bivalent or next-generation molecular glues segment accounted for 38.0% of the market in 2025. Growth in this segment is fueled by advancements in AI-driven design and increasing demand for highly specific therapies. These glues enable the degradation of previously "undruggable" proteins and offer improved pharmacokinetics compared to traditional bifunctional degraders.

🔸 Technology/Process Insights

Phenotypic Screening Led the Market
Phenotypic screening dominated the market in 2025 due to its effectiveness in identifying complex molecular glue mechanisms. It allows researchers to discover new protein degradation pathways and E3 ligase interactions without prior target assumptions.

AI/ML-Driven Discovery Expanding Rapidly
AI and machine learning-based discovery emerged as the second-largest segment. These technologies help overcome the complexity of molecular glue design by identifying novel protein binders and enabling the targeting of difficult disease areas such as cancer and neurological disorders.

High-Throughput Screening (HTS) Showing Strong Growth
HTS is expected to grow significantly due to its ability to rapidly screen large compound libraries. Technologies like NanoBiT, DNA-encoded libraries, and protein microarrays enhance discovery efficiency, while AI integration improves accuracy and reduces false positives.

Structure-Based Drug Design (SBDD) Gaining Traction
SBDD is projected to witness considerable growth as it offers a rational and precise approach to molecular glue design. By using 3D structural data, researchers can engineer molecules that effectively bridge target proteins and E3 ligases.

🔸 Application Insights

Oncology Segment Led the Market
Oncology dominated with a 78.0% market share in 2025, driven by the ability of molecular glues to target and degrade cancer-related proteins. Their role in addressing drug-resistant tumors and the growing need for precision therapies continues to drive adoption.

Neurology Emerging as a Key Segment
Neurology accounted for 10.5% of the market and is expanding due to rising cases of neurodegenerative diseases. Molecular glues offer the advantage of crossing the blood-brain barrier and targeting difficult proteins, supporting future growth.

Immunology Showing Promising Growth
The immunology segment held 8.5% share in 2025 and is expected to grow steadily. This growth is supported by increasing use of molecular glues in modulating immune responses and the success of immunomodulatory drugs in treating autoimmune diseases.

🔸 End-User Insights

Pharmaceutical & Biotechnology Companies Led
Pharma and biotech companies held the largest market share in 2025 due to heavy investments in R&D and demand for advanced drug delivery solutions. Molecular glues offer targeted therapeutic approaches, improving treatment effectiveness and safety.

Academic & Research Institutes Driving Innovation
Academic institutions play a crucial role in discovering new targets and mechanisms, especially for "undruggable" proteins. Their research is expanding applications into neurology, immunology, and rare diseases.

CROs Expected to Grow Fastest
Contract research organizations are projected to grow at the fastest rate. Their expertise, infrastructure, and use of AI, machine learning, and high-throughput technologies enable faster and more efficient molecular glue discovery.

Molecular Glues Market Top Companies and Their Offerings

➢ Bristol Myers Squibb (BMS) partners with Evotec SE on a molecular glue-based pipeline using CELMoDsTM for oncology and other areas, with recent expansions yielding $75M payments and multi-year collaboration.

➢ Novartis AG collaborates with Monte Rosa Therapeutics on VAV1 molecular glue degraders like MRT-6160 (Phase 1 for immune conditions), gaining exclusive rights for up to $2.1B in value.

➢ Monte Rosa Therapeutics develops QuEEN platform molecular glues targeting VAV1 (MRT-6160, Phase 1), NEK7, CDK2, CCNE1; partners with Novartis and Roche for oncology/neurology.

➢ C4 Therapeutics, Inc. uses TORPEDO platform for MonoDAC molecular glues (e.g., CFT7455, Phase 1/2 for multiple myeloma/non-Hodgkin's lymphoma, degrades IKZF1/IKZF3 via CRBN).

➢ Evotec SE collaborates with BMS on molecular glue degraders via multi-omics/AI platforms, focusing on high-value oncology targets beyond traditional small molecules.

➢ Proxygen GmbH offers a ligase-agnostic molecular glue discovery engine; partners with Merck KGaA ($554M) and Boehringer Ingelheim for undruggable cancer targets.

➢ Seed Therapeutics leverages RITE3TM platform accessing 600+ E3 ligases; pipeline includes ST-01156 (Phase 1 for Ewing sarcoma/HCC, RBM39 degrader via DCAF15) and neurodegeneration/oncology programs; partners with Eisai ($1.5B).

➢ Pfizer Inc. partners with Triana Biomedicines (>$1.5B) for oncology molecular glue degraders using target/proximity-first platform.

➢ Roche (Genentech) partners with Monte Rosa (QuEEN for cancer/neurology) and Orionis Biosciences (up to $2B for oncology targets) on molecular glue degraders.

➢ Eli Lilly and Company licensed molecular glue degraders from Magnet Biomedicine (>$1.2B) for undisclosed targets.
Nurix Therapeutics advances DEL-AI platform for molecular glue degraders alongside BTK degraders (NX-5948, NX-2127); partners include Pfizer, Sanofi, Gilead.

➢ Neomorph, Inc. develops molecular glue degraders via proprietary platform; collaborations with Novo Nordisk, Biogen (Alzheimer's/rare/immunology), AbbVie (oncology/immunology, $1.64B).

➢ Kymera Therapeutics discloses molecular glue CDK2 degrader program (oral, oncology incl. breast cancer); option/license with Gilead Sciences.

➢ Arvinas, Inc. primarily focuses on PROTACs (e.g., vepdegestrant/ARV-471 Phase 3 for ER+ breast cancer with Pfizer), with research into molecular glue mechanisms.

➢ Eisai Co., Ltd. partners with Seed Therapeutics ($1.5B) for molecular glue degraders in neurodegeneration and oncology.

Recent Advancements

🔹 AbbVie & Neomorph Collaboration: In January 2025, AbbVie partnered with Neomorph, Inc. to develop molecular glue degraders targeting multiple oncology and immunology targets.

🔹 Cyrus Therapeutics IND Approval: In August 2025, Cyrus Therapeutics received approval from the U.S. FDA for their oral GSPT1 molecular glue degrader candidate CYRS1542, paving the way for clinical trials.

Thank you for reading. You can also get individual chapter-wise sections or region-wise report versions, such as North America, Europe, or Asia Pacific.

📥 Instant Report Delivery Available | 💳 Buy Now 👉 https://www.precedenceresearch.com/checkout/8260

Segment Covered in the Report

🔸 By Type

Monovalent Molecular Glues (Classic glues like IMiDs)
Bivalent/Multispecific Glues (Next-gen rational designs)
CELMoDsTM (Cereblon E3 Ligase Modulating Drugs)
Others (LYTACs, SNIPERs)

🔸 By Application

Oncology (Solid Tumors, Hematologic Malignancies)
Neurology (Alzheimer's, Parkinson's, Neurodegeneration)
Immunology & Inflammation (Autoimmune diseases)
Others

🔸 By Technology/Process

Phenotypic Screening (Serendipitous discovery)
Structure-Based Drug Design (SBDD)
AI/Machine Learning-Enabled Discovery
High-Throughput Screening (HTS)

🔸 By End-User

Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Contract Research Organizations (CROs)

🔸 By Region

North America
Latin America
Europe
Asia-pacific
Middle and East Africa

Connect With Us

📞 USA: +1 804 441 9344
📞 APAC: +61 485 981 310 or +91 87933 22019 | +6531051271
📞 Europe: +44 7383 092 044
📩 Email: sales@precedenceresearch.com

Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

🌐 Web: https://www.precedenceresearch.com

Our Trusted Data Partners:
🔹https://www.towardshealthcare.com
🔹https://www.towardspackaging.com
🔹https://www.towardschemandmaterials.com
🔹https://www.towardsfnb.com
🔹https://www.marketstatsinsight.com

Get Recent News:
https://www.precedenceresearch.com/news

For the Latest Update, Follow Us:
🔹https://www.linkedin.com/company/precedence-research
🔹https://x.com/Precedence_R
🔹https://www.facebook.com/precedenceresearch
🔹https://precedence-research.medium.com/

This release was published on openPR.